A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Episodic Migraine

In brief

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.

Key facts

Study ID

NCT07018700

Run by

Merz Therapeutics GmbH

People needed

990

Starts

2025-08-21

Expected to finish

2027-10-01

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has a diagnosis of EM with or without aura according to current International Classification of Headache Disorders (Edition 3 and Edition 4 alpha) criteria for ≥ 12 months and is able to distinguish migraine headaches from all other types of headaches;
• Participant age < 50 years at the time of migraine onset;
• Participant meeting the following headache and migraine day criteria in each of the 3 months prior to screening: history of ≤ 14 headache days per month and history of 6 to 14 migraine days per month; and
• During the last 28 days of the screening period, participant experiencing: ≤ 14 headache days and 6 to 14 migraine days that qualify as such per the headache diary.

You may not qualify if…

• Diagnosis of chronic migraine;
• Diagnosis of other primary headache types, except tension-type headache, which is permitted;
• Diagnosis of aura without headache, migraine with brainstem aura, hemicrania continua, hypnic headache, hemiplegic migraine, retinal migraine, persistent aura without infarction, migraine aura-triggered seizure, or previous migrainous infarction;
• Diagnosis of secondary headache types, except medication overuse headache, which is permitted;
• Currently taking > 1 prescribed drug for the preventive treatment of migraine;
• Discontinuation of anti-calcitonin gene-related peptide (CGRP) / anti-CGRP receptor monoclonal antibody treatment less than 5 months prior to screening.

Where it is running

• Arizona Neuroscience Research, Merz Investigational Site #0010521 — Phoenix, Arizona, United States (enrolling)
• Baptist Health Medical Center, Merz Investigational Site #0010520 — Little Rock, Arkansas, United States (enrolling)
• Chemidox Clinical Trials Inc, Merz Investigational Site #0010488 — Lancaster, California, United States (enrolling)
• Clinical Research Institute, Merz Investigational Site #0010487 — Los Angeles, California, United States (enrolling)
• Clinical Trials Management Services, Merz Investigational Site #0010526 — Thousand Oaks, California, United States (enrolling)
• BNL Health Inc., Merz Investigational Site #0010489 — Torrance, California, United States (enrolling)
• Hasbani Neurology, Merz Investigational Site #0010509 — New Haven, Connecticut, United States (enrolling)
• Yale Center for Clinical Investigations, Merz Investigational Site #0010527 — New Haven, Connecticut, United States (enrolling)
• New England Institute Neurology and Headache, Merz Investigational Site #0010441 — Stamford, Connecticut, United States (enrolling)
• Northwest Florida Clinical Research Group, Merz Investigational Site #0010286 — Gulf Breeze, Florida, United States (enrolling)
• Nexus Clinical Research Center, Merz Investigational Site #0010514 — Homestead, Florida, United States (enrolling)
• Jacksonville Center for Clinical Research, Merz Investigational Site #0010515 — Jacksonville, Florida, United States (enrolling)
• Clinical Research of Central Florida, Merz Investigational Site #0010532 — Lakeland, Florida, United States (enrolling)
• American Research Institute, Merz Investigational Site #0010492 — Miami, Florida, United States (enrolling)
• Premiere Research Institute at Palm Beach Neurology, Merz Investigational Site #0010499 — West Palm Beach, Florida, United States (enrolling)
• Accel Research - NeuroStudies, Merz Investigational Site #0010523 — Decatur, Georgia, United States (enrolling)
• Hawaii Pacific Neuroscience, Merz Investigational Site #0010510 — Honolulu, Hawaii, United States (enrolling)
• Kansas Institute of Research,, Merz Investigational Site #0010495 — Overland Park, Kansas, United States (enrolling)
• Crescent City Headache and Neurology Center, Merz Investigational Site #0010517 — Chalmette, Louisiana, United States (enrolling)
• DelRicht Clinical Research,, Merz Investigational Site #0010518 — New Orleans, Louisiana, United States (enrolling)
• Sinai Hospital of Baltimore, Merz Investigational Site #0010505 — Baltimore, Maryland, United States (enrolling)
• MedVadis Research, Merz Investigational Site #0010524 — Waltham, Massachusetts, United States (enrolling)
• Mass Institute of Clinical Research, Merz Investigational Site #0010506 — Westborough, Massachusetts, United States (enrolling)
• Vida Clinical Studies, Merz Investigational Site #0010498 — Dearborn Heights, Michigan, United States (enrolling)
• TrialSphere Corp, Merz Investigational Site #0010513 — Chandler, Arizona, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.